GET DAILY SIGNALSWhy Is Globus Medical (GMED) Stock Down -8.19% Today?
Key Takeaways
- Globus Medical (GMED) shares fell 8.19% in today's session, dropping from a prior close of $81.44 to roughly $74.77.
- The primary catalyst was third-quarter earnings: revenue missed expectations and management cut its full-year revenue outlook.
- Secondary drivers included a reported analyst downgrade to Market Perform and a sharp giveback after the stock's roughly 9% surge earlier in the week.
- Weakness in the U.S. Spine franchise, delayed product launches, and a steep decline in the Nevro segment weighed on the top line even as earnings beat estimates.
- Traders are now watching whether margin strength and a larger buyback program can offset a visibly decelerating growth story into 2027.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages for GMED.
- Discover how AI-powered trading strategies are navigating this volatility on the Trending AI Robots page.
Opening Summary
Globus Medical, Inc. (GMED), a musculoskeletal medical device company specializing in spine, orthopedic trauma, joint reconstruction, and enabling technologies such as surgical robotics and navigation, saw its stock slide sharply on Thursday. Shares traded down 8.19% to approximately $74.77, versus a prior session close of $81.44, after the company reported third-quarter results that revealed a top-line miss and a cut to its full-year revenue guidance. The market reaction centered on slowing growth in the core U.S. Spine business, delayed product launches, and continued weakness in the recently acquired Nevro pain-management segment, which together overshadowed an otherwise solid earnings beat and strong margins.
Earnings Results and Revenue Guidance Cut
The most consequential driver of today's decline was the company's third-quarter report. GMED posted non-GAAP earnings per share of $1.23, slightly above the $1.20 consensus estimate. However, revenue of $763.7 million came in below the roughly $792 million analysts had expected and declined about 0.7% year over year. More importantly, management lowered its full-year 2026 revenue guidance to approximately $3.09 billion, down from a prior range of $3.18 billion to $3.22 billion, implying slower growth of roughly 5.1%. While the company reaffirmed its non-GAAP EPS guidance of $4.95 to $5.05, investors focused on the stalling top line, sending shares lower.
Spine Slowdown and Delayed Product Launches
Beneath the headline numbers, the deceleration was broad-based. Growth in the U.S. Spine segment slowed to roughly 2%, a marked step down from the high-single-digit expansion recorded earlier in 2026. Management attributed the slowdown to timing delays around key new product introductions, lingering production issues, and weaker-than-expected contributions from competitive sales representative recruiting. Products such as the SCRIPT patient-specific implant line and the XLIF Prone solution have slipped in timing, with much of their revenue contribution now expected to materialize in 2027 rather than the second half of 2026.
Nevro Weakness and International Pressure
The Nevro segment, acquired to expand GMED into the spinal cord stimulation and pain market, remained a notable drag. Nevro revenue fell approximately 25.7% year over year to $73.7 million, as earlier declines in U.S. trial volumes continued to weigh on results. International sales also declined 5.7%, with management citing integration disruption and softness in certain regions. Excluding Nevro, the base business grew just 3.0%, underscoring how the broader portfolio's momentum has cooled relative to prior quarters.
Analyst Downgrade and Market Context
Compounding the earnings-driven selloff, reports indicated that analysts at BMO downgraded the stock to Market Perform, adding further selling pressure. The move also reflects a giveback of recent gains: GMED had jumped about 9% earlier in the week, so today's decline partly unwinds that rally. Trading volume was elevated relative to recent sessions, consistent with heavy institutional repositioning following the report. The stock's slide occurred against a backdrop of broader softness among medical device and orthopedic peers, though the company-specific guidance cut was the dominant factor.
What Comes Next for GMED
Looking ahead, investors will be watching whether GMED can translate its margin strength and robust free cash flow into renewed revenue growth. Management has positioned 2027 as a product-led growth year, anchored by the SCRIPT, XLIF Prone, and EIQ launches, as well as the planned HFX Elite device in the Nevro franchise. The company also authorized a $500 million increase to its share repurchase program, which may provide some support. Key risks include further launch slippage, ongoing Nevro recovery challenges, and a competitive spine market. Upcoming earnings and product-launch milestones will be closely scrutinized as the market gauges whether the slowdown is temporary or more structural.
Trending AI Robots
Tickeron's Trending AI Robots page highlights AI-driven trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are curated into the Trending AI Robots section, helping traders identify momentum and opportunities across shifting market environments. Explore the page to see which strategies are adapting to today's volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GMED in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for GMED crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
GMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 213 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 23 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 62 cases where GMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 52 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for GMED turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
GMED moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.137). P/E Ratio (17.897) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of spinal implants
Industry MedicalNursingServices
Advertisement